AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
2.650
+0.080 (3.11%)
Aug 15, 2025, 4:00 PM - Market closed
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $16.00K in the quarter ending March 31, 2025, a decrease of -60.00%. This brings the company's revenue in the last twelve months to $146.00K, down -24.35% year-over-year. In the year 2024, AIM ImmunoTech had annual revenue of $170.00K, down -15.84%.
Revenue (ttm)
$146.00K
Revenue Growth
-24.35%
P/S Ratio
57.84
Revenue / Employee
$6,348
Employees
23
Market Cap
7.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AIM News
- 18 hours ago - AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 day ago - AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 9 days ago - AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) - GlobeNewsWire
- 11 days ago - AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval - GlobeNewsWire
- 18 days ago - Why Is Micro-Cap AIM ImmunoTech Stock Surging? - Benzinga
- 6 weeks ago - AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements - GlobeNewsWire
- 2 months ago - AIM ImmunoTech Resumes Trading on NYSE American - GlobeNewsWire